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Breakdown of the inner blood-retinal barrier (iBRB) occurs early in diabetes and is central to the development of sight-threatening
diabetic macular edema (DME) as retinopathy progresses. In the current study, we examined how advanced glycation end prod-
ucts (AGEs) forming early in diabetes could modulate vasopermeability factor expression in the diabetic retina and alter inter-
endothelial cell tight junction (TJ) integrity leading to iBRB dysfunction. We also investigated the potential for an AGE inhibitor
to prevent this acute pathology and examined a role of the AGE-binding protein galectin-3 (Gal-3) in AGE-mediated cell retinal
pathophysiology. Diabetes was induced in C57/BL6 wild-type (WT) mice and in Gal-3−/− transgenic mice. Blood glucose was
monitored and AGE levels were quantified by ELISA and immunohistochemistry. The diabetic groups were subdivided, and one
group was treated with the AGE-inhibitor pyridoxamine (PM) while separate groups ofWT and Gal-3−/− mice were maintained as
nondiabetic controls. iBRB integrity was assessed by Evans blue assay alongside visualisation of TJ protein complexes via occludin-
1 immunolocalization in retinal flat mounts. Retinal expression levels of the vasopermeability factor VEGF were quantified us-
ing real-time RT-PCR and ELISA. WT diabetic mice showed significant AGE -immunoreactivity in the retinal microvasculature
and also showed significant iBRB breakdown (P < .005). These diabetics had higher VEGF mRNA and protein expression in
comparison to controls (P < .01). PM-treated diabetics had normal iBRB function and significantly reduced diabetes-mediated
VEGF expression. Diabetic retinal vessels showed disrupted TJ integrity when compared to controls, while PM-treated diabetics
demonstrated near-normal configuration. Gal-3−/− mice showed significantly less diabetes-mediated iBRB dysfunction, junctional
disruption, and VEGF expression changes than their WT counterparts. The data suggests an AGE-mediated disruption of iBRB via
upregulation of VEGF in the diabetic retina, possibly modulating disruption of TJ integrity, even after acute diabetes. Prevention
of AGE formation or genetic deletion of Gal-3 can eﬀectively prevent these acute diabetic retinopathy changes.
Copyright © 2007 Paul Canning et al. This is an open access article distributed under the Creative Commons Attribution License,
which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
1. INTRODUCTION
Breakdown of the inner blood-retinal barrier (iBRB) is a se-
rious pathophysiological lesion in diabetic patients and if
left untreated can lead to sight-threatening diabetic macu-
lar edema (DME), see [1, 2]. There are various approaches to
quantification of iBRB dysfunction in patients, but irrespec-
tive of the technique employed [3, 4], it is established that this
lesion occurs early in clinical diabetic retinopathy [5] and is
associated with progression of the disease [6]. Breakdown of
the iBRB is also a feature of experimental diabetes in animal
models, being observed as early as 1-2-week postdiabetes in-
duction in rodents [7, 8].
The precise mechanism of iBRB compromise during
diabetic retinopathy remains incompletely elucidated but
there are firm links with diabetes-mediated upregulation of
the potent vasopermeability factor VEGF from the neural
retina [9]. VEGFmodulates loss of tight junction integrity or
enhanced transport mechanisms in endothelial cells in the
early stages of diabetic retinopathy [10, 11]. Upregulation
of this growth factor occurs early in diabetes [12] which
suggests that expression may be linked to acute hyper-
glycemia, alteration in retinal blood flow, and/or enhanced
proinflammatory processes influencing retinal capillary
function. Treatment of diabetic rodents with a range of
agents that either modulate protein kinase C activation [13],
prevent formation of reactive oxygen species (ROS) [14],
or regulate aldose reductase activity [15, 16] can prevent
diabetes-mediated rises in VEGF expression and prevent
iBRB dysfunction.
The formation of advanced glycation end products (AGEs)
is an important pathogenic mechanism indiabetic retinopathy.
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These adducts form on the amino groups of proteins, lipids,
and DNA through nonenzymatic glycation reactions with
glucose and also through highly reactive α-oxoaldehydes
such as glyoxal, (GO), methylglyoxal (MGO), and 3-
deoxyglucosone (3-DG) which can form AGEs very rapidly
[17]. In support of clinical correlates, AGE-adducts are
known to accumulate intracellularly in neurones and vas-
cular cells, and extracellularly on basement membranes of
diabetic retina [18–20] where they mediate pathophysio-
logical changes [21–23]. Advanced glycation reactions also
have relevant pathogenic eﬀects on retinal vascular cells in
vitro; responses that may, in part, be mediated through a
range of AGE-binding proteins and receptors with defined
proinflammatory signalling capacity and ability to modulate
AGE-mediated pathophysiology [24–26].
In terms of iBRB function, AGEs are known to induce
expression of the potent vasopermability agent VEGF in the
retina in vivo [21, 27], or in retinal cells in vitro [28, 29]. Fur-
thermore, these adducts can disrupt endothelial junctional
complexes [30] and induce hyperpermeability in retinal cap-
illary endothelial monolayers [31]. In vivo, AGEs have been
linked to breakdown of the iBRB during diabetic retinopa-
thy through infusion of preformed, highly modified “model
AGEs” into nondiabetic animals which cause leakage of albu-
min and concomitant increases in VEGF mRNA expression
[21, 32]. To date there have been no studies on the possibility
of preventing acute VEGF upregulation or iBRB dysfunction
using AGE inhibitors. Therefore, in the current study we have
examined how AGEs, formed early in diabetes, could modu-
late vasopermeability factor expression in the diabetic retina
and alter interendothelial cell tight junction integrity lead-
ing to iBRB dysfunction. Previous studies have shown a role
for galectin-3 (Gal-3) in modulation of some AGE-mediated
responses [26] therefore we have also investigated the con-
tribution of this multifunctional lectin in AGE-mediated cell
retinal pathophysiology in short-term diabetes.
2. MATERIALS AND METHODS
2.1. Animals and induction of diabetes
Both Gal-3−/− and corresponding wild-type (WT) C57/BL6
controls at 6-8-week old were used in this study. All animals
were housed and cared for in accordance with the ARVO
Statement for the Use of Animals in Ophthalmic and Vi-
sion Research and to British Home oﬃce regulations. Gal-3
knockout mice (Gal-3−/−) were generated and backcrossed
to C57/BL6 for 9 generations as previously described by Hsu
et al. [33]. Male Gal-3−/− and WT control animals were
rendered diabetic with a single intraperitoneal injection of
streptozotocin, 165mg/kg in sterile filtered citrate buﬀer pH
4.6 (Sigma Chemical Company, Poole, England) as has been
previously reported [34]. Nondiabetic WT animals were in-
jected with an equivalent volume of citrate buﬀer alone.
Blood glucose levels were measured one week postdiabetes
induction and animals with glucose readings greater than
15mmol/L were included in the study. A subset of diabetic
animals subsequently received the AGE-inhibitor pyridox-
amine (PM; pyridoxamine dihydrochloride, Biostratum Inc.,
Durham, NC, USA) administered orally in the drinking wa-
ter (1 g/L).Water intake from all mice groups wasmonitored.
Three weeks postdiabetes induction, and immediately prior
to experimentation, animals were reweighted and blood glu-
cose levels were remeasured to confirm diabetic status.
2.2. Assessment of AGEs in retina
Three weeks postdiabetes induction, 6 animals per group
were euthanized by asphyxiation with carbon dioxide, the
eyes enucleated, and retinas dissected under an operating
microscope before being flash frozen in liquid nitrogen and
stored at −80◦C. The brain and the kidneys were also re-
moved, flash frozen, and stored at −80◦C. Protein was ex-
tracted by homogenising the retinal, brain, and kidney tissue
extracts, respectively, in radioimmunoprecipitation buﬀer
(RIPA; consisting of 0.5M Tris-HCl, pH 6.8 containing 10%
(w/v) SDS), over ice. Total protein was quantified by BCA as-
say (Pierce, MSC, Dublin, Ireland), and equivalent amounts
loaded for AGE quantification by competitive ELISA using
a polyclonal antibody to carboxymethyllysine (CML) (kind
gift from Dr. Suzanne Thorpe, University of South Carolina,
Columbia, SC, USA), see [22].
2.3. Assessment of blood-retinal barrier breakdown
Plasma albumin leakage from the diabetic retinal vascula-
ture and hence iBRB dysfunction were quantified in using
Evans blue in accordance with the published protocol [8]
with modifications as outlined by Brankin et al. [35]. Briefly,
Evans blue dye (Sigma), was dissolved in PBS (30mg/mL),
sonicated for 5 minutes, and filtered through a 0.45 μm fil-
ter. Nondiabetic, diabetic, and PM-treated diabetic wild-type
and Gal-3−/− mice (n = 8/group) were anaesthetized with
isofluorane and Evans blue dye intravenously administered
by tail vein injection (26 g, Venisystems Ltd., Abbot Ireland
Ltd., Sligo, Eire) at a dose of 45mg/kg in a volume of 200 μL
upon which mice were seen to turn blue, and this was used
as a confirmation that the dye had been taken into the blood-
stream.
Quantification of dye leakage into the neuropile was as-
sayed as previously described [8]. Briefly, 3 hours after Evan’s
blue injection the mice were perfused using citrate buﬀer at
a pressure of 120mm/Hg (for up to 2 minutes). Both eyes
were enucleated and retinas were removed. After determina-
tion of the wet weight, the retinas were completely dried by
placing in a Speed-Vac overnight at 60◦C. Retinal dry weights
were subsequently determined, and retinas then crushed in
120 μL formamide at 70◦C for 18 hours, in order to remove
Evan’s blue. After this time, the extract was centrifuged with
a filter centrifuge tube at 15 000 rpm for 30 minutes in order
to remove retinal debris. The filtrate was subsequently read
on the spectrophotometer at an absorbance of 620 nm, the
absorbance maximum for Evan’s blue, and 740 nm, the ab-
sorbance minimum. The concentration of dye in the extracts
was calculated from a standard curve of Evan’s blue in for-
mamide. The BRB breakdown was calculated as outlined by
Qaum et al. [8].
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For visual assessment of leakage, animals were deeply
anaesthetized using ketamine/xylazine and 40 kd FITC-
Dextran (Sigma) (30mg/mL in sterile PBS) injected into
the left ventricle. The tracer was allowed to circulate for
∼2 minutes and the eyes were then enucleated and imme-
diately fixed in 4% PFA. The eyes were fixed overnight in
2% paraformaldehyde and the following day the retinas were
dissected oﬀ, cut in a Maltese cross-configuration, and flat-
mounted onto glass slides. The retinas were then viewed us-
ing epifluorescence.
2.4. Quantification of retinal VEGF mRNA and protein
Animals were treated as described previously and eyes enu-
cleated immediately following sacrifice (n = 6/group). Reti-
nas were dissected away from the posterior eye cup and
placed in an RNA stabilisation reagent (RNAlater, Ambion,
Austin, Tex, USA) and stored at 4◦C. Total retinal RNA was
extracted with Tri-reagent (Sigma) by standard isopropanol:
chloroform precipitation as described in the manufacturer’s
instructions. The resulting RNA pellets were washed twice
with 75% ethanol, and resuspended in 30 μL diethyl pyro-
carbonate (DEPC) treated water. RNA integrity and quality
were confirmed by analysis of 260 : 280 nm absorbance ra-
tio, and visualisation of ribosomal 28 s and 18 s bands on
a 1% agarose gel. cDNA was synthesized from 2 μg retinal
RNA using a reverse transcriptase cDNA synthesis kit (Im-
Prom II, Promega, MSC, Dublin, Ireland) according to man-
ufacturer’s instructions on an automated Applied Biosystems
2720 Thermal Cycler.
cDNA was diluted twenty-fold prior to PCR amplifica-
tion. Real-time PCR analysis was performed for quantitative
analysis of mRNA expression. A 189 bp-fragment of VEGF
cDNA was amplified with murine-specific primers (forward:
5′ TTACTGCTGTACCTCCACC 3′; reverse: 5′ ACAGGA-
CGGCTTGAAGATG 3′). In addition, primers to amplify
a 100 bp-fragment of the housekeeping gene 28 s ribosomal
RNA were used: (forward 5′ TTGAAAATCCGGGGGAGA-
G 3′; reverse 5′ ACATTGTTCCAACATGCCAG 3′). Real-
time RT-PCR was performed with an ABI Prism 7000 Se-
quence Detection system. PCR was performed in a 96-well
plate format (ABgen, Rochester, NY, USA), in a 20 μL vol-
ume, containing 0.5 μM primers, reaction buﬀer, 2.5mM
MgCl2, dNTPs, Taq DNA polymerase (hotstart), and SYBER
green I fluorescent dye (Qiagen, Crawley, UK). Amplification
involved an initial 15-minute denaturation step, followed by
up to 45 cycles of a 95◦C denaturation for 15 seconds, 52–
58◦C annealing for 20 seconds, and 72◦C for an appropriate
extension time (5–25 seconds). Fluorescence of the green dye
that was bound to the PCR product was detected at the end
of each extension period and the specificity of the amplifica-
tion reactions confirmed by melting curve analysis and sub-
sequent agarose gel electrophoresis. PCR amplification reac-
tions were performed in triplicate on material from at least
two independent reverse transcription reactions. Quantifica-
tion data was analysed by the delta Ct method [36], and nor-
malised to the housekeeping gene 28 s ribosomal RNA.
For VEGF protein quantification, retinas were freshly dis-
sected, and placed in 200 μL RIPA buﬀer supplemented with
protease inhibitor cocktail (Roche, Mannheim, Germany).
Retina was homogenised with a plastic pestle and hand held
battery rotor, and sonicated. The lysate was centrifuged at
13 000 rpm for 5 minutes, and the resulting supernatants as-
sayed for VEGF activity using the Quantikine Mouse VEGF
Immunoassay kit (R&D Systems) as per the manufacturer’s
instructions.
2.5. Immunohistochemistry
The retinal vasculature was visualised by reaction with bi-
otinylated isolectin B4 from Griﬀonia Simplicifolia (Sigma-
Aldrich Ltd., Gillingham, UK) at 50 ng/mL followed by
streptavidin-Alexa 568 (Molecular Probes Europe BV, Lei-
den, Netherlands). Retinal flatmounts were washed exten-
sively and mounted in Vectasheild (Vector Laboratories Ltd.,
Peterborough, UK). Images were acquired using an Olympus
BX60 fluorescence microscope (Olympus UK Ltd., London,
UK) fitted with a MicroRadiance confocal scanning laser
microscope (CSLM) (Bio-Rad Laboratories, Hercules, Calif,
USA).
For methylglyoxal (MG)-derived AGE immunolocaliza-
tion, one eye from 5 animals from each treatment regime
was fixed in 4% PFA for 4 hours and then washed ex-
tensively over a 4-hour period after which the anterior
segment-lens complexes were removed and the posterior
eye cups relaxed by placing 4 radial cuts from the reti-
nal periphery to points within 1mm from the optic disc.
The posterior eye cups were permeabilised and nonspe-
cific immunoreactive sites blocked for 16 hourrs at 4◦C in
PBS containing 0.5% Triton X-100 (TX-100), 5% normal
goat serum and mouse-on-mouse reagent (Vector Laborato-
ries, Youngstown, Ohio, USA). Monoclonal anti-MG mod-
ified protein antibody (kindly donated by Dr. Ryoji Na-
gai, Kumamoto University, Kumamoto, Japan) or control
mouse IgG (Sigma) was added to the retinas overnight at
4◦C at 1 : 1000 dilution in PBS containing 0.5% TX-100.
The retinas were then blocked in 5% NGS in permeabilis-
ing buﬀer, washed extensively, and exposed to antimouse-
488 nm Alexa (Molecular Probes Inc., Eugene, Ore, USA),
diluted 1 : 500 in PBS containing TX-100 for 3 hours at
4◦C. The retinas were then washed extensively, mounted in
Citifluor (Agar Scientific Ltd., Essex, England) on micro-
scope slides and immunofluorescence detected by CSLM.
Gain settings were kept constant between specimens dur-
ing digital confocal image capture, in order to compare the
intensity of immunoreactivity in the retina between treat-
ment groups.
For occludin immunolocalization, 5 eyes from animals
from each treatment group were enucleated and fixed in 70%
ethanol for 30 minutes at 4◦C. Following this initial fixation,
eyes were transferred to acetone that had been prechilled at
−20◦C, and fixed for further 3 minutes. Retinas were dis-
sected, blocked, and permeabilised with blocking reagent
(PBS, 0.5% Triton X-100, and 5% goat serum) overnight at
4◦C, prior to incubation with mouse antioccludin primary
antibody (Zymed Laboratories, South San Francisco, Calif,
USA) (1 : 3000 dilution in blocking reagent) for two days
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Table 1: Metabolic parameters and AGE accumulation in tissues from diabetic (DB) and nondiabetic (NDB) mice. Blood glucose levels are
significantly higher in the diabetic groups when compared to nondiabetic controls. There is no diﬀerence between WT and Gal-3−/− mice,
nor does pyridoxamine (PM) have any eﬀect on hyperglycaemia. DiabeticWT and Gal-3−/− mice also show characteristic loss of weight when
compared to their respective nondiabetic counterparts. Retinal CML-immunoreactivity is elevated in WT diabetic mice when compared to
nondiabetic controls (P < .05). Nondiabetic Gal-3−/− animals have significantly less retinal CML when compared toWT control and PM has
no appreciable influence on CML accumulation over this 2-week time frame. As reference tissues, kidney and brainCML-immunoreactivities
are elevated in diabetes in WT and Gal-3−/− mice (± standard deviation).
CML (pg CML/mg protein)
Weight Blood glucose Brain Kidney Retina
WT NDB 27.5± 2.08 15.85± 5.44 58.73± 8.64 299.57± 86.0 81.77
WT DB 19.15± 2.87∗ 30.99± 5.97∗∗ 60.60± 6.26 341.28± 137.63 87.42∗
WT DB PM 19.10± 4.51∗ 28.23± 8.26∗∗ 60.29± 8.54 348.29± 115.44 89.65∗
Gal-3−/− NDB 24.24± 1.97 12.46± 4.78 64.13± 3.98 386.19± 135.17 72.09∗
Gal-3−/− DB 22.14± 2.07 30.46± 4.05 69.66± 4.99 310.79± 224.41 87.18
Gal-3−/− DB PM 20.50± 1.78 28.76± 6.11 66.45± 5.68 281.73± 48.90 89.14
∗P < .05.
∗∗P < .001.
at 4◦C. Retinas were washed six times in PBS and incubated
with a goat antimouse Alexa 488 nm secondary antibody
(1 : 2000 dilution in block solution) (Invitrogen, Paisley, UK)
for 2 hours at room temperature. Retinas were washed for
further six times in PBS (20 minutes each, as previously) be-
fore flat mounting on microscope slides by making four ra-
dial cuts in aMaltese cross-configuration. Flat-mounted reti-
nas were visualised using CSLM as outlined above.
3. RESULTS
3.1. Diabetes and formation of AGEs
Blood glucose levels were elevated in the diabetic groups
when compared to nondiabetic (P < .001) and there was
no diﬀerence between WT and Gal-3−/− groups (Table 1).
PM had no significant influence on hyperglycaemia in either
Gal-3−/− or WT mice (Table 1). Diabetic WT and Gal-3−/−
also exhibited characteristic loss of weight when compared
to their respective nondiabetic counterparts (Table 1).
As determined by competitive ELISA, CML levels were
modestly but significantly elevated in the retinas of WT dia-
betic mice when compared to nondiabetic controls (P < .05).
Nondiabetic Gal-3−/− animals had significantly less retinal
CML when compared to WT control (P <.05). Diabetes in-
creased this CML-immunoreactivity in Gal-3−/− animals. In
all cases, PM had no appreciable influence on this parame-
ter (Table 1). For reference, kidney and brain from animals
recruited to this study were also assessed for AGEs. It was
determined that CML was elevated in diabetes in WT and
Gal-3−/− mice. In kidney, absence of Gal-3 reduced the CML
content after 3-week diabetes (P < .05).
Isolectin staining showed the microvascular tree in the
retinal flatmounts (Figures 1(a) and 1(b)). Immunohisto-
chemistry using a monoclonal antibody that recognises MG-
derived adducts showed localization to the intraretinal mi-
crovasculature, both in terms of the superficial and deep cap-
illary plexi. In all diabetic mice examined there was marked
increase in vascular staining when compared to nondia-
betic controls (compare Figure 1(c) with Figure 1(d)). PM-
treatment reduced this MG-adduct immunofluorescence
(Figure 1(e)) and in all controls (in which mouse-on-mouse
block was used) negative staining was observed (Figure 1(f)).
3.2. Blood-retinal barrier function
Breakdown of the BRB as determined by Evans blue dye leak-
age, was up to 4-fold greater after 2-week diabetes in WT
mice compared to nondiabetic controls (P < .005). PM-
treatment of diabetic animals significantly prevented this va-
sopermeability response, to the extent that there was no sig-
nificant diﬀerence between nondiabetic and PM-treated dia-
betic WT mice (Figure 2). Gal-3−/− mice failed to demon-
strate any diabetes-mediated increase in BRB dysfunction
which contrasted markedly with their WT counterparts
(Figure 2).
3.3. Tight junction integrity
Leakage of FITC-dextran of 40 kd was evident in diabetic
retinas while nondiabetic controls showed no leakage of this
tracer (compare Figures 3(a) and 3(b)). Diabetes also had
a profound eﬀect on integrity of tight junctions, as deter-
mined by immunolocalization of the junctional complex
component protein occludin in retinal flatmounts. Im-
munostaining for occludin-1 demonstrated integrity of the
tight junctions between arterial, capillary, and venous en-
dothelium in the nondiabetic WT animals (Figure 3(c)).
Diabetes significantly altered this configuration, with less
defined occludin-immunoreactivity in TJ complexes, show-
ing a cytoplasmic staining pattern rather than being lo-
calised at the plasma membrane (Figure 3(e)). PM treat-
ment seemed to restore some of this integrity in diabetic an-
imals (Figure 3(g)). In contrast to WT counterparts, the reti-
nal microvasculature of Gal-3−/− demonstrated integrity of
tight junctions, not only in nondiabetic controls but also in
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(a) (b)
(c) (d)
(e) (f)
Figure 1: AGE accumulation in the diabetic retina. Lectin staining
shows the vascular tree in (a) nondiabetic and (b) diabetic animals.
At such an acute time frame of diabetes, there is no appreciable dif-
ference in density of capillaries. Also on retinal flat mounts, an anti-
body that recognizes MG-derived AGEs shows modest immunore-
activity in the retinal-microvasculature in nondiabetic mice (c).
Diabetic mice (d) show considerably more intense AGE labelling,
again largely within the retinal-blood vessels which are only par-
tially reduced in diabetics treated with PM (e). Controls show only
background immunoreactivity (f). Original magnification x200.
diabetic and nondiabetic animals treated with PM (Figures
3(d), 3(f), and 3(h)).
3.4. VEGF expression
ELISA showed that after only two weeks of diabetes in WT
mice VEGF peptide was increased twofold over nondiabetic
controls (P < .01) (Figure 4(a)). PM-treatment showed a
significant, albeit incomplete, reduction in this diabetes-
mediated increase (P < .05). The Gal-3−/− animals had a
much lower baseline level of VEGF when nondiabetic WT
NDB DB DB
PM
NDB DB DB
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Figure 2: Inner blood-retinal barrier (iBRB) function in diabetic
WT and Gal-3−/− mice. As determined by Evan’s blue assay, di-
abetic animals (DB) show a significant increase in BRB dysfunc-
tion when compared to nondiabetic (NDB) controls. Pyridoxamine
(PM) treated diabetic animals do not show this vasopermeability re-
sponse and are more comparable to nondiabetic controls. Gal-3−/−
fails to demonstrate diabetes-induced barrier dysfunction.
was compared with the transgenic counterpart (P < .001).
VEGF levels were increased upon induction of diabetes in
the Gal-3−/− mice and while the magnitude of change was
comparable to WT, the VEGF levels in Gal-3−/− were still
lower than nondiabetic WT. PM treatment of Gal-3−/− di-
abetic mice increased VEGF relative to diabetic counterparts
(P < .01) (Figure 4(a)).
For all relative mRNA expression data, data was nor-
malised to the housekeeping gene ribosomal 28 s, and re-
sults were expressed relative to the levels in the WT non-
diabetic control group. VEGF mRNA fluctuation correlated
closely with the trend seen for Evans blue leakage between
the various treatment groups of animals. VEGF mRNA ex-
pression was almost three-fold higher in the untreated WT
diabetic control group compared to the nondiabetic controls
(P < .01) (Figure 4(b)). PM treatment reduced this increase
in diabetic VEGF mRNA levels (P < .05). In the correspond-
ing Gal-3−/− animals, the diabetes-induced increase in reti-
nal VEGF mRNA expression was less pronounced than in
WT. Nevertheless, PM treatment decreased the VEGFmRNA
expression levels to less than those measured in the nondia-
betic control animal group (P < .01) (Figure 4(b)).
4. DISCUSSION
Breakdown of the iBRB is an established lesion in clinical
diabetes. Abnormal microvascular leakage can occur early
after establishment of diabetes although it remains uncer-
tain how this relates to more severe, sight-threatening mac-
ular oedema. For study of iBRB dysfunction in experimental
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(a) (b)
(c) (d)
(e) (f)
(g) (h)
Figure 3: Diabetes alters tight junction integrity in retinal capillar-
ies. Fluorescein dextran angiography on retinal flat mounts shows
integrity of the retinal microvasculature in nondiabetic mice (a)
while there is a clear leakage of tracer (∼40 kd) into the retinal neu-
ropile in 2-week diabetic animals (b) (original magnification x100).
Fluorescent immunostaining for occludin-1 of retinal flat mounts
from nondiabetic WT mice demonstrates plasma membrane local-
ization at the tight junctions (TJs) of the endothelium (c). By con-
trast with diabetic animals, there is aggregation of occludin-1 in
the cytoplasm of endothelial cells rather than at the plasma mem-
brane (e). PM treatment of diabetic mice only partially prevents
disruption of the junctional integrity (g). Nondiabetic (d), diabetic
(f), and PM-treated Gal-3−/− mice (h) show none of the diabetes-
induced changes observed in WT counterparts (original magnifica-
tion x200).
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Figure 4: VEGF protein andmRNA expression in diabetic Gal-3−/−
and WT mouse retina. In WT mice (black bars) VEGF expression
is significantly increased in diabetic (DB) retina—in terms of both
protein (a) and mRNA expression (b) when compared to nondi-
abetic controls (NDB). PM-treatment significantly reduces VEGF
expression in diabetic mice. In Gal-3−/− mice (white bars), retinal
expression levels are not as dramatically increased by the presence
of diabetes as evidenced in WT mice.
diabetes most focus has been placed on short-term retinopa-
thy models in rodents where acute phase vasopermeability
is evident after only 2-3-week diabetes [7, 8]. Various studies
have shown that manipulation of adhesion molecules, proin-
flammatory cytokines, and nitric oxide can prevent this le-
sion within an acute time frame [7, 8, 37, 38]. The current
study has demonstrated that AGE inhibition by PM, soon af-
ter diabetes induction, also prevents iBRB dysfunction with
concomitant VEGF upregulation and loss of tight junction
integrity.
Advanced glycation is an important pathogenic factor in
diabetic retinopathy and most other vascular complications
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of diabetes [39]. AGE-modifications are usually consid-
ered to take months or years to accumulate in diabetic
tissues, but it is now clear that these adducts can also
form rapidly during hyperglycaemia [19]. Exposure of
retinal glial and vascular cells to high glucose in vitro can
induce significant AGE formation after 7–10 days [40, 41],
leading to modifications that have profound pathogenic
consequences [41–43]. Hyperglycaemia-linked formation
of highly reactive α-oxaloaldehydes is a major source of
these rapidly formed intra- and extracellular adducts such as
Nε-(carboxymethyl)lysine (CML), Nε-(carboxyethyl)lysine
(CEL), and MG-derived hydroimidazolone [17]. Indeed,
MG is raised in serum from diabetic patients [44] and
the immunolocalization data in the current study suggests
that AGEs derived from this dicarbonyl also accumulate
in the retinal microvasculature of acutely diabetic mice.
MG-derived AGEs have been shown to occur in retinal
microvascular endothelial cells exposed for 10 days to high
glucose in vitro which is within the time boundaries of the
current in vivo study [40]. MG-modifications have been
shown to induce profound cell responses such as altering
transcriptional regulation of vasoactive growth factors [41].
MG-modifications of the basement membrane also induce
dysfunctional responses in retinal microvascular endothelial
cells [45] and it is reasonable to assume that rapid formation
of both intracellular and extracellular MG-modifications in
vivo has pathogenic implications for endothelial dysfunction
and iBRB compromise during acute diabetes.
Inhibitors of advanced glycation have shown eﬃcacy in
reducing retinal microvascular lesions in diabetic animal
models [22, 23, 46]. With direct relevance to the current
study, PM has been shown to have beneficial eﬀects by pre-
venting CML formation and subsequent lesion formation
in diabetic retinopathy in a rat model over a 7-month time
frame [22] with an eﬃcacy that is comparable to other di-
abetic complications [47]. We have now demonstrated that
PM is also eﬀective against iBRB dysfunction within an acute
treatment regime. The mechanism of this action is proba-
bly linked to the ability of PM to prevent MG-derived AGE
formation as evidenced by the present immunohistochem-
istry data in combination with previous studies that have
demonstrated PM eﬃcacy against MG-derived AGEs [48].
Perhaps unsurprisingly there was no eﬀect of PM treatment
on non-MG-derived CML formation over this short time
frame in retina, kidney, or brain which contrasted with pre-
viously reported long-term outcomes [22]. It is interest-
ing that PM could have short-term benefit over a signifi-
cant diabetic retinopathy lesion and, while more investiga-
tion is required, this could indicate applicability for anti-
AGE strategies over a shorter time frame than previously
thought.
AGEs have been linked to increases in retinal VEGF ex-
pression although the precise mechanism for this remains
uncertain [49]. Since the major sources of VEGF expres-
sion in the retina are Muller glia and ganglion cells it would
seem that these cells are influenced by AGE adducts either
through endogenous formation or as a response to expo-
sure from leaked AGE-modified serum proteins. We have
previously shown that Muller glia and ganglion cells accu-
mulate AGE adducts (CML) over 7-month diabetes [22],
but following more acute exposure to hyperglycaemia it is
possible that these cells could form significant AGEs and re-
spond by upregulating VEGF. MG-modification of the tran-
scriptional corepressor protein mSin3A has been shown as
the mechanism whereby retinal levels of the growth factor
angiopoietin-2 are upregulated in Muller glia in vitro [41].
It is interesting that most of the MG-derived protein modifi-
cations in the inner retina were vascular-localised with lesser
immunoreactivity in the Muller glia. The reason for this is
unclear but it is possible that acute hyperglycaemia has most
immediate impact on the endothelium and that longer peri-
ods of high glucose exposure are required to raise intracel-
lular levels of AGEs in the retinal neuropile. The chemical
nature, time frame of formation, and cellular localization of
various AGEs are important parameters to establish and such
studies are currently ongoing in our laboratory.
The current investigation indicates that iBRB dysfunc-
tion in diabetes is modulated by the presence of Gal-3. This
multifunctional protein has a diverse range properties linked
to its carbohydrate binding capacity and may be involved in
immune processes and neoplastic disease [50]. Gal-3 also has
AGE-binding properties and several diabetes-related patho-
physiological responses are mediated, at least in part, by Gal-
3 (also referred to as AGE-R3 [51]). The role of Gal-3 as an
AGE-binding protein with links to diabetic microvasculopa-
thy has been previously demonstrated [52–54] and this pro-
tein also plays a significant role in AGE-related pathophysiol-
ogy during diabetic retinopathy. We have previously demon-
strated that Gal-3−/− mice or neutralisation with a Gal-3 an-
tibody reversed the inhibition of retinal angiogenesis by di-
abetic sera or exogenous AGEs [26]. The presence of Gal-3
appears to be required for iBRB dysfunction during acute di-
abetes where it may modulate cell responses to AGEs. How
this occurs is uncertain, especially when one considers that
exogenous AGEs (whether occurring as modified serum pro-
teins or as substrate-immobilized cross-links) are not signifi-
cantly diﬀerent in 2-week diabetics and nondiabetic controls.
It remains possible that Gal-3 could alter vascular cell func-
tion independent of AGE binding or that the protein could
bind to intracellular adducts illicit cell stability against AGE-
induced changes.
It is entirely possible that Gal-3 could modulate barrier
dysfunction during diabetes by mechanisms that are addi-
tional to, or distinct from, AGE binding. Beyond an AGE
binding role, various possibilities can be suggested for Gal-
3 modulation of iBRB dysfunction in diabetes. Gal-3 binds
many substrate proteins including collagen IV, fibronectin,
and elastin and is a main element in promoting cell adhe-
sion [50]. It is also interesting to note that this protein has a
distinct role in immune responses and it has been shown to
promote mast cell activation and proinflammatory signals in
a number of tissues, characterised by promoting adhesion of
neutrophils and monocytes to endothelial cells [50, 55]. In-
deed, Gal-3−/− mice show reduced inflammatory responses
during peritonitis [56] while macrophages from these an-
imals have attenuated phagocytic capacity when compared
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to wild-type controls [57]. iBRB compromise in diabetic
retinopathy is not necessarily separate from these proin-
flammatory processes, indeed, during diabetes the retinal
microvasculature shows enhanced expression of endothe-
lial ICAM-1/VCAM-1 adhesion molecules and promotion
of capillary leukostasis [37, 38]. AGEs have been shown to
promote these responses in the murine retina [21, 32]. In-
vestigations into the links between Gal-3, retinal capillary
leukostasis, and iBRB dysfunction are ongoing. More re-
search needs to be conducted on Gal-3 and its ability to reg-
ulate pathogenic responses in diabetic retinopathy, perhaps
with respect to interaction with the well-characterised AGE
receptor RAGE [54].
ACKNOWLEDGMENTS
The authors acknowledge the technical contribution of Mr.
Matt Owen and Mr. Stephen Lloyd. Financial support from
The Wellcome Trust, The Belfast Association for the Blind,
and The Juvenile Diabetes Research Foundation (JDRF) is
gratefully acknowledged.
REFERENCES
[1] R. J. Antcliﬀ and J. Marshall, “The pathogenesis of edema in
diabetic maculopathy,” Seminars in Ophthalmology, vol. 14,
no. 4, pp. 223–232, 1999.
[2] C. Engler, B. Krogsaa, and H. Lund-Andersen, “Blood-retina
barrier permeability and its relation to the progression of di-
abetic retinopathy in type 1 diabetes. An 8-year follow-up
study,” Graefe’s Archive for Clinical and Experimental Ophthal-
mology, vol. 229, no. 5, pp. 442–446, 1991.
[3] B. Sander, M. Larsen, C. Engler, et al., “Diabetic macular
oedema: a comparison of vitreous fluorometry, angiography,
and retinopathy,” British Journal of Ophthalmology, vol. 86,
no. 3, pp. 316–320, 2002.
[4] G. L. Trick, J. Liggett, J. Levy, et al., “Dynamic contrast en-
hanced MRI in patients with diabetic macular edema: initial
results,” Experimental Eye Research, vol. 81, no. 1, pp. 97–102,
2005.
[5] M. S. Roy, M. J. Podgor, P. Bungay, G. Grunberger, J. Carl, and
D. Ellis, “Posterior vitreous fluorophotometry in diabetic pa-
tients with minimal or no retinopathy,” Retina, vol. 7, no. 3,
pp. 170–176, 1987.
[6] J. Cunha-Vaz, C. Lobo, J. C. Sousa, B. Oliveiros, E. Leite, and J.
R. Faria de Abreu, “Progression of retinopathy and alteration
of the blood-retinal barrier in patients with type 2 diabetes: a
7-year prospective follow-up study,” Graefe’s Archive for Clini-
cal and Experimental Ophthalmology, vol. 236, no. 4, pp. 264–
268, 1998.
[7] A. B. El-Remessy, M. A. Behzadian, G. Abou-Mohamed, T.
Franklin, R. W. Caldwell, and R. B. Caldwell, “Experimental
diabetes causes breakdown of the blood-retina barrier by a
mechanism involving tyrosine nitration and increases in ex-
pression of vascular endothelial growth factor and urokinase
plasminogen activator receptor,” American Journal of Pathol-
ogy, vol. 162, no. 6, pp. 1995–2004, 2003.
[8] T. Qaum, Q. Xu, A. M. Joussen, et al., “VEGF-initiated blood-
retinal barrier breakdown in early diabetes,” Investigative Oph-
thalmology and Visual Science, vol. 42, no. 10, pp. 2408–2413,
2001.
[9] R. H. Amin, R. N. Frank, A. Kennedy, D. Eliott, J. E. Puk-
lin, and G. W. Abrams, “Vascular endothelial growth factor is
present in glial cells of the retina and optic nerve of human
subjects with nonproliferative diabetic retinopathy,” Investiga-
tive Ophthalmology and Visual Science, vol. 38, no. 1, pp. 36–
47, 1997.
[10] D. A. Antonetti, A. J. Barber, L. A. Hollinger, E. B.Wolpert, and
T. W. Gardner, “Vascular endothelial growth factor induces
rapid phosphorylation of tight junction proteins occludin and
zonula occluden 1. A potential mechanism for vascular per-
meability in diabetic retinopathy and tumors,” Journal of Bio-
logical Chemistry, vol. 274, no. 33, pp. 23463–23467, 1999.
[11] A. J. Barber and D. A. Antonetti, “Mapping the blood vessels
with paracellular permeability in the retinas of diabetic rats,”
Investigative Ophthalmology and Visual Science, vol. 44, no. 12,
pp. 5410–5416, 2003.
[12] S. Ishida, T. Usui, K. Yamashiro, et al., “VEGF164 is proinflam-
matory in the diabetic retina,” Investigative Ophthalmology and
Visual Science, vol. 44, no. 5, pp. 2155–2162, 2003.
[13] L. P. Aiello, S.-E. Bursell, A. Clermont, et al., “Vascular en-
dothelial growth factor-induced retinal permeability is medi-
ated by protein kinase C in vivo and suppressed by an orally
eﬀective β-isoform-selective inhibitor,”Diabetes, vol. 46, no. 9,
pp. 1473–1480, 1997.
[14] R. Rota, C. Chiavaroli, R. P. Garay, and P. Hannaert, “Reduc-
tion of retinal albumin leakage by the antioxidant calcium
dobesilate in streptozotocin-diabetic rats,” European Journal of
Pharmacology, vol. 495, no. 2-3, pp. 217–224, 2004.
[15] A. K. H. Cheung, M. K. L. Fung, A. C. Y. Lo, et al., “Aldose
reductase deficiency prevents diabetes-induced blood-retinal
barrier breakdown, apoptosis, and glial reactivation in the
retina of db/db mice,”Diabetes, vol. 54, no. 11, pp. 3119–3125,
2005.
[16] I. G. Obrosova, A. G. Minchenko, R. Vasupuram, et al., “Al-
dose reductase inhibitor fidarestat prevents retinal oxidative
stress and vascular endothelial growth factor overexpression in
streptozotocin-diabetic rats,” Diabetes, vol. 52, no. 3, pp. 864–
871, 2003.
[17] S. R. Thorpe and J. W. Baynes, “Maillard reaction products in
tissue proteins: new products and new perspectives,” Amino
Acids, vol. 25, no. 3-4, pp. 275–281, 2003.
[18] H.-P. Hammes, A. Alt, T. Niwa, et al., “Diﬀerential accumula-
tion of advanced glycation end products in the course of di-
abetic retinopathy,” Diabetologia, vol. 42, no. 6, pp. 728–736,
1999.
[19] N. Karachalias, R. Babaei-Jadidi, N. Ahmed, and P. J. Thor-
nalley, “Accumulation of fructosyl-lysine and advanced glyca-
tion end products in the kidney, retina and peripheral nerve
of streptozotocin-induced diabetic rats,” Biochemical Society
Transactions, vol. 31, part 6, pp. 1423–1425, 2003.
[20] A. W. Stitt, Y. M. Li, T. A. Gardiner, R. Bucala, D. B. Archer,
and H. Vlassara, “Advanced glycation end products (AGEs)
co-localize with AGE receptors in the retinal vasculature of di-
abetic and of AGE-infused rats,” American Journal of Pathol-
ogy, vol. 150, no. 2, pp. 523–531, 1997.
[21] A. W. Stitt, T. Bhaduri, C. B. T. McMullen, T. A. Gardiner, and
D. B. Archer, “Advanced glycation end products induce blood-
retinal barrier dysfunction in normoglycemic rats,” Molecular
Cell Biology Research Communications, vol. 3, no. 6, pp. 380–
388, 2000.
[22] A. W. Stitt, T. A. Gardiner, N. L. Anderson, et al., “The AGE
inhibitor pyridoxamine inhibits development of retinopathy
in experimental diabetes,” Diabetes, vol. 51, no. 9, pp. 2826–
2832, 2002.
Paul Canning et al. 9
[23] T. A. Gardiner, H. R. Anderson, and A. W. Stitt, “Inhibition of
advanced glycation end-products protects against retinal cap-
illary basement membrane expansion during long-term dia-
betes,” Journal of Pathology, vol. 201, no. 2, pp. 328–333, 2003.
[24] A. Bierhaus, M. A. Hofmann, R. Ziegler, and P. P. Nawroth,
“AGEs and their interaction with AGE-receptors in vascular
disease and diabetes mellitus. I. The AGE concept,” Cardiovas-
cular Research, vol. 37, no. 3, pp. 586–600, 1998.
[25] A. M. Schmidt, S. D. Yan, S. F. Yan, and D. M. Stern, “The
multiligand receptor RAGE as a progression factor amplifying
immune and inflammatory responses,” Journal of Clinical In-
vestigation, vol. 108, no. 7, pp. 949–955, 2001.
[26] A.W. Stitt, C.McGoldrick, A. Rice-McCaldin, et al., “Impaired
retinal angiogenesis in diabetes: role of advanced glycation end
products and galectin-3,” Diabetes, vol. 54, no. 3, pp. 785–794,
2005.
[27] M. Lu, M. Kuroki, S. Amano, et al., “Advanced glycation end
products increase retinal vascular endothelial growth factor
expression,” Journal of Clinical Investigation, vol. 101, no. 6,
pp. 1219–1224, 1998.
[28] S.-I. Yamagishi, H. Yonekura, Y. Yamamoto, et al., “Advanced
glycation end products-driven angiogenesis in vitro: induction
of the growth and tube formation of humanmicrovascular en-
dothelial cells through autocrine vascular endothelial growth
factor,” Journal of Biological Chemistry, vol. 272, no. 13, pp.
8723–8730, 1997.
[29] S. McFarlane, J. V. Glenn, A. M. Lichanska, D. A. C. Simp-
son, and A. W. Stitt, “Characterisation of the advanced glyca-
tion endproduct receptor complex in the retinal pigment ep-
ithelium,” British Journal of Ophthalmology, vol. 89, no. 1, pp.
107–112, 2005.
[30] K. Otero, F. Martı´nez, A. Beltra´n, et al., “Albumin-derived ad-
vanced glycation end-products trigger the disruption of the
vascular endothelial cadherin complex in cultured human and
murine endothelial cells,” Biochemical Journal, vol. 359, part 3,
pp. 567–574, 2001.
[31] G. Leto, F. Pricci, L. Amadio, et al., “Increased retinal en-
dothelial cell monolayer permeability induced by the diabetic
milieu: role of advanced non-enzymatic glycation and polyol
pathway activation,” Diabetes/Metabolism Research and Re-
views, vol. 17, no. 6, pp. 448–458, 2001.
[32] T. C. B. Moore, J. E. Moore, Y. Kaji, et al., “The role of
advanced glycation end products in retinal microvascular
leukostasis,” Investigative Ophthalmology and Visual Science,
vol. 44, no. 10, pp. 4457–4464, 2003.
[33] D. K. Hsu, R.-Y. Yang, Z. Pan, et al., “Targeted disruption of the
galectin-3 gene results in attenuated peritoneal inflammatory
responses,” American Journal of Pathology, vol. 156, no. 3, pp.
1073–1083, 2000.
[34] O. T. Cox, D. A. C. Simpson, A. W. Stitt, and T. A. Gardiner,
“Sources of PDGF expression in murine retina and the eﬀect
of short-term diabetes,” Molecular Vision, vol. 10, no. 9, pp.
665–672, 2003.
[35] B. Brankin, M. Campbell, P. Canning, T. A. Gardiner, and A.
W. Stitt, “Endostatin modulates VEGF-mediated barrier dys-
function in the retinal microvascular endothelium,” Experi-
mental Eye Research, vol. 81, no. 1, pp. 22–31, 2005.
[36] D. A. Simpson, S. Feeney, C. Boyle, and A. W. Stitt, “Reti-
nal VEGF mRNA measured by SYBR green I fluorescence:
a versatile approach to quantitative PCR,” Molecular Vision,
vol. 6, pp. 178–183, 2000.
[37] A. M. Joussen, V. Poulaki, N. Mitsiades, et al., “Nonsteroidal
anti-inflammatory drugs prevent early diabetic retinopathy
via TNF-α suppression,” The FASEB Journal, vol. 16, no. 3, pp.
438–440, 2002.
[38] A. M. Joussen, V. Poulaki, W. Qin, et al., “Retinal vascu-
lar endothelial growth factor induces intercellular adhesion
molecule-1 and endothelial nitric oxide synthase expression
and initiates early diabetic retinal leukocyte adhesion in vivo,”
American Journal of Pathology, vol. 160, no. 2, pp. 501–509,
2002.
[39] A. W. Stitt and T. M. Curtis, “Advanced glycation and retinal
pathology during diabetes,” Pharmacological Reports, vol. 57
supplement, pp. 156–168, 2005.
[40] P. S. Padayatti, C. Jiang, M. A. Glomb, K. Uchida, and R.
H. Nagaraj, “High concentrations of glucose induce synthe-
sis of argpyrimidine in retinal endothelial cells,” Current Eye
Research, vol. 23, no. 2, pp. 106–115, 2001.
[41] D. Yao, T. Taguchi, T. Matsumura, et al., “Methylglyoxal mod-
ification of mSin3A links glycolysis to angiopoietin-2 tran-
scription,” Cell, vol. 124, no. 2, pp. 275–286, 2006.
[42] I. Giardino, D. Edelstein, and M. Brownlee, “Nonenzymatic
glycosylation in vitro and in bovine endothelial cells alters ba-
sic fibroblast growth factor activity. A model for intracellu-
lar glycosylation in diabetes,” Journal of Clinical Investigation,
vol. 94, no. 1, pp. 110–117, 1994.
[43] A. W. Stitt, U. Chakravarthy, D. B. Archer, and T. A. Gardiner,
“Increased endocytosis in retinal vascular endothelial cells
grown in high glucose medium is modulated by inhibitors of
nonenzymatic glycosylation,” Diabetologia, vol. 38, no. 11, pp.
1271–1275, 1995.
[44] D. S. Fosmark, P. A. Torjesen, B. K. Kilhovd, et al., “In-
creased serum levels of the specific advanced glycation end
product methylglyoxal-derived hydroimidazolone are associ-
ated with retinopathy in patients with type 2 diabetes melli-
tus,” Metabolism, vol. 55, no. 2, pp. 232–236, 2006.
[45] D. J. McKenna, J. Nelson, and A. W. Stitt, “Advanced glycation
alters expression of the 67kDa laminin receptor in retinal mi-
crovascular endothelial cells,” Life Sciences, vol. 68, no. 24, pp.
2695–2703, 2001.
[46] H.-P. Hammes, D. Strodter, A.Weiss, R. G. Bretzel, K. Federlin,
and M. Brownlee, “Secondary intervention with aminoguani-
dine retards the progression of diabetic retinopathy in the rat
model,” Diabetologia, vol. 38, no. 6, pp. 656–660, 1995.
[47] N. L. Alderson,M. E. Chachich, N. N. Youssef, et al., “The AGE
inhibitor pyridoxamine inhibits lipemia and development of
renal and vascular disease in Zucker obese rats,” Kidney Inter-
national, vol. 63, no. 6, pp. 2123–2133, 2003.
[48] R. H. Nagaraj, P. Sarkar, A. Mally, K. M. Biemel, M. O. Led-
erer, and P. S. Padayatti, “Eﬀect of pyridoxamine on chemical
modification of proteins by carbonyls in diabetic rats: char-
acterization of a major product from the reaction of pyridox-
amine and methylglyoxal,” Archives of Biochemistry and Bio-
physics, vol. 402, no. 1, pp. 110–119, 2002.
[49] C. Treins, S. Giorgetti-Peraldi, J. Murdaca, and E. Van Ob-
berghen, “Regulation of vascular endothelial growth factor
expression by advanced glycation end products,” Journal of Bi-
ological Chemistry, vol. 276, no. 47, pp. 43836–43841, 2001.
[50] J. Dumic, S. Dabelic, and M. Flo¨gel, “Galectin-3: an open-
ended story,” Biochimica et Biophysica Acta (BBA)—General
Subjects, vol. 1760, no. 4, pp. 616–635, 2006.
[51] H. Vlassara, R. Bucala, and L. Striker, “Pathogenic eﬀects of
advanced glycosylation: biochemical, biologic, and clinical im-
plications for diabetes and aging,” Laboratory Investigation,
vol. 70, no. 2, pp. 138–151, 1994.
10 Experimental Diabetes Research
[52] W. Zhu, H. Sano, R. Nagai, K. Fukuhara, A. Miyazaki, and S.
Horiuchi, “The role of galectin-3 in endocytosis of advanced
glycation end products and modified low density lipopro-
teins,” Biochemical and Biophysical Research Communications,
vol. 280, no. 4, pp. 1183–1188, 2001.
[53] G. Pugliese, F. Pricci, G. Leto, et al., “The diabetic milieu mod-
ulates the advanced glycation end product-receptor complex
in the mesangium by inducing or upregulating galectin-3 ex-
pression,” Diabetes, vol. 49, no. 7, pp. 1249–1257, 2000.
[54] G. Pugliese, F. Pricci, C. Iacobini, et al., “Accelerated diabetic
glomerulopathy in galectin-3/AGE receptor 3 knockout mice,”
The FASEB Journal, vol. 15, no. 13, pp. 2471–2479, 2001.
[55] F.-T. Liu, R. J. Patterson, and J. L. Wang, “Intracellular func-
tions of galectins,” Biochimica et Biophysica Acta (BBA)—
General Subjects, vol. 1572, no. 2-3, pp. 263–273, 2002.
[56] C. Colnot, M.-A. Ripoche, G. Milon, X. Montagutelli, P. R.
Crocker, and F. Poirier, “Maintenance of granulocyte numbers
during acute peritonitis is defective in galectin-3-null mutant
mice,” Immunology, vol. 94, no. 3, pp. 290–296, 1998.
[57] H. Sano, D. K. Hsu, J. R. Apgar, et al., “Critical role of galectin-
3 in phagocytosis by macrophages,” Journal of Clinical Investi-
gation, vol. 112, no. 3, pp. 389–397, 2003.
AUTHOR CONTACT INFORMATION
Paul Canning: Centre for Vision Science, Queen’s University
Belfast, Royal Victoria Hospital, Grosvenor Road, Belfast BT12
6BA, Northern Ireland, UK; p.canning@talk21.com
Josephine V. Glenn: Centre for Vision Science, Queen’s
University Belfast, Royal Victoria Hospital, Grosvenor Road,
Belfast BT12 6BA, Northern Ireland, UK; j.v.glenn@qub.ac.uk
Daniel K. Hsu: Department of Dermatology, School of Medicine,
University of California, Sacramento, CA 95616, USA;
dkhsu@ucdavis.edu
Fu-Tong Liu: Department of Dermatology, School of Medicine,
University of California, Sacramento, CA 95616, USA;
fliu@ucdavis.edu
Tom A. Gardiner: Centre for Vision Science, Queen’s University
Belfast, Royal Victoria Hospital, Grosvenor Road, Belfast BT12
6BA, Northern Ireland, UK; t.gardiner@qub.ac.uk
Alan W. Stitt: Centre for Vision Science, Queen’s University
Belfast, Royal Victoria Hospital, Grosvenor Road, Belfast BT12
6BA, Northern Ireland, UK; a.stitt@qub.ac.uk
Submit your manuscripts at
http://www.hindawi.com
Stem Cells
International
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2014
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2014
MEDIATORS
INFLAMMATION
of
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2014
Behavioural 
Neurology
Endocrinology
International Journal of
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2014
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2014
Disease Markers
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2014
BioMed 
Research International
Oncology
Journal of
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2014
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2014
Oxidative Medicine and 
Cellular Longevity
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2014
PPAR Research
The Scientific 
World Journal
Hindawi Publishing Corporation 
http://www.hindawi.com Volume 2014
Immunology Research
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2014
Journal of
Obesity
Journal of
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2014
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2014
 Computational and  
Mathematical Methods 
in Medicine
Ophthalmology
Journal of
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2014
Diabetes Research
Journal of
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2014
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2014
Research and Treatment
AIDS
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2014
Gastroenterology 
Research and Practice
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2014
Parkinson’s 
Disease
Evidence-Based 
Complementary and 
Alternative Medicine
Volume 2014
Hindawi Publishing Corporation
http://www.hindawi.com
